What is Akynzeo? Akynzeo contains a combination of netupitant and palonosetron
It is not known if Akynzeo is safe and effective in children under 18 years of age
Akynzeo (netupitant / palonosetron) is a combination of two medications, netupitant and palonosetron, that's used with dexamethasone to prevent nausea and vomiting caused by certain anti-cancer medications (chemotherapy)
5 and clinical studies administration schedule in section 5
For patients receiving a highly emetogenic chemo medicine, the doctor may also prescribe AKYNZEO for injection is compatible with intravenous dexamethasone sodium phosphate which can be added to the infusion bag containing AKYNZEO solution or infused simultaneously
INDICATION
AKYNZEO capsules is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy
A more than two-fold increase in the systemic exposure of dexamethasone was observed 4 days after a single dose of netupitant or a single infusion of fosnetupitant Administer 3 medications at once by simultaneously infusing AKYNZEO and dexamethasone* *Do not add dexamethasone to the AKYNZEO injection (ready-to-use) vial
This should not be a concern if you are receiving dexAMETHasone in combination with netupitant for the prevention of nausea and vomiting associated with cancer chemotherapy, since the AKYNZEO injection (Ready-to-Use) contains no antimicrobial preservatives and is intended for single use only
AKYNZEO capsules can be taken with or without food
In all studies, dexamethasone was coadministered with Akynzeo (see Section 5
1
The plasma concentrations of CYP3A4 substrates can increase when co-administered with AKYNZEO
The inhibitory effect on CYP3A4 can last for multiple days Dexamethasone doses should be reduced when given with AKYNZEO
Treatment Akynzeo (Netupitant and Palonosetron), a Dual-Acting Oral Agent, Approved by the FDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting
: 268600 Akynzeo® is a registered trademark Knight TherapeuticsInc
The inhibitory effect on CYP3A4 can last for multiple days Dexamethasone doses should be reduced when given with AKYNZEO
A more than two-fold increase in the systemic exposure of dexamethasone was observed 4 days after a single dose of netupitant or a single infusion of fosnetupitant AKYNZEO ® inhibits 2 nausea A more than two-fold increase in the systemic exposure of dexamethasone was observed 4 days after a single dose of netupitant or a single infusion of fosnetupitant; Consider the potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam Use with caution in patients receiving concomitant medications primarily metabolized by CYP3A4
It is marketed and distributed by Helsinn Therapeutics
49% of reviewers reported a positive effect, while 36% reported a negative Dexamethasone 8 mg once a day
Infuse over 30 minutes starting 30 minutes before chemotherapy [see Dosage and Administration (2
; Serotonin syndrome has been reported with 5-HT 3 receptor antagonists alone but particularly with concomitant use of The recommended dosages of AKYNZEO and dexamethasone in adults for the prevention of nausea and vomiting associated with administration of emetogenic chemotherapy are shown in Table 1
It is not known if AKYNZEO is safe and effective in children under 18 years of age
Use with caution in patients receiving concomitant medications primarily metabolized by CYP3A4
Its generic name is Netupitant + Palonosetron
" AKYNZEO is used in combination with the medicine dexamethasone in people to help prevent the nausea and vomiting that happens right away or later with certain anti-cancer medicines (chemotherapy)
AKYNZEO ® provides cancer care teams with two antiemetics in a single oral fixed dose combination capsule
The recommended dosages of AKYNZEO and dexamethasone in adults for the prevention of nausea and vomiting associated with administration of emetogenic chemotherapy are shown in
Treatment Akynzeo is available as capsules and as a powder to be made up into a solution for injection
" AKYNZEO is used in combination with the medicine dexamethasone in people to help prevent the nausea and vomiting that happens right away or later with certain anti-cancer medicines (chemotherapy)
Reference ID: 5126804
Akynzeo (netupitant / palonosetron) is a combination of two medications, netupitant and palonosetron, that's used with dexamethasone to
5 mg hard capsules - Summary of Product Characteristics (SmPC) - (emc) Active Ingredient: palonosetron hydrochloride, netupitant
AKYNZEO capsules is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated
425 adult cancer patients receiving a non-AC HEC regimen received palonosetron (PALO) plus
AKYNZEO capsules is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial
" AKYNZEO is used in combination with the medicine dexamethasone in people to help prevent the nausea and vomiting that happens right away or later with certain anti-cancer medicines (chemotherapy)
Do not add dexamethasone sodium phosphate to the AKYNZEO
AKYNZEO for injection and AKYNZEO injection are indicated in combination with
, Suite 1055 Montreal, Quebec Canada H3Z 3B8 90% of AKYNZEO patients receiving cisplatin had no vomiting and no rescue antiemetic medication use over 5 days 1 Complete response rate with a single dose of AKYNZEO capsules + dexamethasone (primary endpoint) in patients treated with cisplatin 1,2 (Primary endpoint)
Plain language summary Chemotherapy-induced nausea and vomiting (CINV) is a common problem during cancer treatment
Primary endpoint was complete response in the overall phase
Your doctor will ask you to take other medicines including a corticosteroid (such as dexamethasone) to prevent you feeling and being sick
It is marketed and distributed by Helsinn Therapeutics
73% of reviewers reported a positive effect, while 19% reported a negative effect
AKYNZEO for injection and AKYNZEO injection contain no antimicrobial preservatives, are intended for single use only and are compatible with intravenous dexamethasone sodium phosphate which can be added to the AKYNZEO solution or
5 mg + dexamethasone 20 mg 1; Days 2-3: No antiemetic treatment 1; The efficacy of AKYNZEO for injection and AKYNZEO injection for the prevention of CINV has not been established in a clinical study of patients treated with AC chemotherapy 1
It is not known if AKYNZEO is safe and effective in children under 18 years of age
Use with caution in patients receiving concomitant medications primarily metabolized by CYP3A4